ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) shares shot up 3.7% on Thursday . The company traded as high as $6.18 and last traded at $6.18. 732,865 shares changed hands during trading, a decline of 81% from the average session volume of 3,952,584 shares. The stock had previously closed at $5.96.
Wall Street Analyst Weigh In
Separately, Piper Sandler lifted their price objective on shares of ImmunityBio from $4.00 to $5.00 and gave the stock a "neutral" rating in a research report on Monday, March 25th.
Check Out Our Latest Analysis on IBRX
ImmunityBio Price Performance
The stock has a market cap of $4.10 billion, a PE ratio of -5.14 and a beta of 1.23. The firm's 50 day moving average price is $5.01 and its two-hundred day moving average price is $3.88.
Hedge Funds Weigh In On ImmunityBio
Several large investors have recently modified their holdings of IBRX. Swiss National Bank increased its stake in shares of ImmunityBio by 9.2% in the first quarter. Swiss National Bank now owns 188,000 shares of the company's stock worth $1,055,000 after purchasing an additional 15,900 shares in the last quarter. MetLife Investment Management LLC grew its stake in ImmunityBio by 28.5% in the 1st quarter. MetLife Investment Management LLC now owns 33,258 shares of the company's stock worth $187,000 after buying an additional 7,377 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in ImmunityBio by 3.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 493,059 shares of the company's stock worth $2,767,000 after buying an additional 16,672 shares in the last quarter. Vident Investment Advisory LLC grew its stake in ImmunityBio by 19.7% in the 1st quarter. Vident Investment Advisory LLC now owns 201,588 shares of the company's stock worth $1,131,000 after buying an additional 33,112 shares in the last quarter. Finally, State Street Corp grew its stake in ImmunityBio by 8.8% in the 1st quarter. State Street Corp now owns 6,760,306 shares of the company's stock worth $37,925,000 after buying an additional 544,929 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.
Read More
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
